¼ò
¤™
- ¼ò
- ·±
- EN
-
¹ØÓÚvic3308 ¤™
-
¿Æ¼¼Á¢Òì ¤™
-
²úÆ·ÓëÓªÒµ ¤™
-
ÐÂÎÅÖÐÐÄ ¤™
-
Ͷ×ÊÕß¹Øϵ ¤™
-
ESG ¤™
-
Ö°ÒµÉú³¤ ¤™
¼ò
¤™
±¾´Î´ó»á½ÒÏþµÄÊ¥ÂÞÀ³?Ñо¿Ð§¹ûÀ´×ÔÌìÏÂÊ®¶à¸ö²î±ðÊ¡ÊеÄÒ½Ôº£¬£¬£¬£¬£¬ £¬£¬£¬ÄÚÈÝ°üÀ¨ÅàĪɳëĵÄÕæʵÌìÏÂÑо¿¡¢²¡Àý±¨¸æºÍ»úÖÆÑо¿µÈ£¬£¬£¬£¬£¬ £¬£¬£¬²»µ«ÆÀ¹ÀÁËÅàĪɳëÄÔÚ͸Îö/·Ç͸ÎöÂýÐÔÉöÔಡ£¡£¡£¡£¡£¡£¨CKD£©ÑªÐ黼ÕßÖеÄÁÆЧºÍÇå¾²ÐÔ£¬£¬£¬£¬£¬ £¬£¬£¬»¹Ì½Ë÷ÁËÅàĪɳëÄÔÚÉöÒÆÖ²¡¢´¿ºìϸ°ûÔÙÉúÕÏ°ÐÔѪÐ飨PRCA£©¡¢ºìϸ°ûÌìÉú´Ì¼¤¼Á£¨ESA£©µÍ·´Ó¦ÒÔ¼°ÄÑÖÎÐÔÉöÐÔѪÐéµÈ¸ü¶àϸ·ÖÈËȺÖеÄÓ¦Ó㬣¬£¬£¬£¬ £¬£¬£¬´Ó¶øΪÉöÐÔѪÐéÁÙ´²Êµ¼ùÖÐÃæÁÙµÄÖî¶àÒÉÄÑÌôÕ½ÌṩеĽâ¾ö¼Æ»®¡£¡£¡£¡£¡£¡£
ÒÔÏÂÊDZ¾´Î¾Û»áÊÕ¼µÄÅàĪɳëÄÏà¹Ø±Ú±¨¼°ÂÛÎÄ[1]¡£¡£¡£¡£¡£¡£
1.´Ùºìϸ°ûÌìÉúËØÄ£ÄâëÄÅàĪɳëÄÖÎÁÆ·Ç͸ÎöÒÀÀµÐÍ 1 ÐÍÌÇÄò²¡Éö²¡»¼Õß´¿ºìϸ°ûÔÙÉúÕÏ°ÐÔѪÐé
×÷ÕߣºÉϺ£ÊеÚÒ»ÈËÃñÒ½Ôº ·¶ÇïÁ飬£¬£¬£¬£¬ £¬£¬£¬µÈ
2.ÅàĪɳëÄ×¢ÉäÒºÔÚ³õʼ¸¹Ä¤Í¸Îö»¼ÕßÖÐÓÐÓÃÐÔÓëÇå¾²ÐÔµÄÕæʵÌìÏÂÑо¿
×÷ÕߣººÓÄϿƼ¼´óѧµÚÒ»Á¥ÊôÒ½Ôº ³£½à£¬£¬£¬£¬£¬ £¬£¬£¬µÈ
3.ÅàĪɳëÄÀÖ³ÉÖÎÁÆEPOÓÕµ¼µÄ´¿ºìϸ°ûÔÙÉúÕÏ°ÐÔƶ£¨PRCA)1Àý
×÷ÕߣºÄϲý´óѧµÚÒ»Á¥ÊôÒ½Ôº Û³ÑÞ£¬£¬£¬£¬£¬ £¬£¬£¬µÈ
4.ÆÀ¹ÀEMPÔÚѪҺ͸Îö»¼ÕßѪÐé¼°ÐÄѪ¹Ü»ñÒæµÄÁÆЧÑо¿
×÷ÕߣºÖØÇìÒ½¿Æ´óѧÁ¥Êô´óѧ³ÇÒ½Ôº ÑîÓ°£¬£¬£¬£¬£¬ £¬£¬£¬µÈ
1.Efficacy and Safety of Pegmolesatide in Kidney Transplant Recipients with anemia
×÷ÕߣºËÄ´¨´óѧ»ªÎ÷Ò½Ôº ʯÔËÓ¨£¬£¬£¬£¬£¬ £¬£¬£¬µÈ
2.EPO-Mimetic Peptide Pegmolesatide Therapy for Pure Red Cell Aplasia in a Patient with Non-dialysis- dependent Type 1 Diabetic Nephropathy: A Case Report
×÷ÕߣºÉϺ£ÊеÚÒ»ÈËÃñÒ½Ôº ·¶ÇïÁ飬£¬£¬£¬£¬ £¬£¬£¬µÈ
3.ÅàĪɳëÄͨ¹ýÒÖÖÆEPOR/CD131-JAK2/STAT3ͨ·¸ÄÉÆCKDÏàÌåÌù¼¡Ï¸°û·Ê´ó
×÷Õߣº±±¾©´óѧÈËÃñÒ½Ôº ×óÁ¦£¬£¬£¬£¬£¬ £¬£¬£¬µÈ
4.ÅàĪɳëÄÖÎÁÆÂýÐÔÉöÔಡÉöÐÔѪÐé1ÖÜʱµÄÔçÆÚÁÆЧÓëÇå¾²ÐÔ£ºÒ»Ïî»ØÊ×ÐÔÐÐÁÐÑо¿
×÷ÕߣºËÄ´¨´óѧ»ªÎ÷Ò½Ôº ¸¶Æ½£¬£¬£¬£¬£¬ £¬£¬£¬µÈ
5.ÅàĪɳëÄ×¢ÉäÒºÖÎÁÆѪ͸»¼ÕßÉöÐÔѪÐéµÄÓÐÓÃÐÔºÍÇå¾²ÐÔÑо¿
×÷Õߣº¸´µ©´óѧÁ¥ÊôÖÐɽҽԺ ¶¡Ð¡Ç¿£¬£¬£¬£¬£¬ £¬£¬£¬µÈ
6.ÅàĪɳëÄÔÚ½ÓÊܹý´Ùºìϸ°ûÌìÉúËØÖÎÁƵÄ͸ÎöÈËȺÖÐÓÐÓÃÐÔºÍÇå¾²ÐÔ:Ò»ÏîÕæʵÌìÏÂÑо¿
×÷ÕߣºÄþ²¨´óѧÁ¥ÊôµÚÒ»Ò½Ôº ±ßѧÑ࣬£¬£¬£¬£¬ £¬£¬£¬µÈ
7.ÅàĪɳëÄÖÎÁÆ´Ùºìϸ°ûÌìÉúËصͷ´Ó¦Î¬³ÖÐÔѪҺ͸Îö»¼ÕßµÄÁÆЧÆÊÎö
×÷Õߣº¸£½¨Ê¡ÄþµÂÊÐÃö¶«Ò½Ôº ÁÖÌÚÇ¿£¬£¬£¬£¬£¬ £¬£¬£¬µÈ
8.ÅàĪɳëÄÖÎÁÆÉöÐÔѪÐéµÄÑÖ¤Ñо¿Ï£Íû
×÷ÕߣºÊ¯¼ÒׯÊеÚÈýÒ½Ôº ²ÜÒ带£¬£¬£¬£¬£¬ £¬£¬£¬µÈ
9.ÅàĪɳëÄÖÎÁÆÂýÐÔÉöÔಡ·Ç͸ÎöÉöÐÔѪÐ黼ÕßÁÆЧ¼°Çå¾²ÐÔÆÀ¹À
×÷ÕߣººÓÄϿƼ¼´óѧµÚÒ»Á¥ÊôÒ½Ôº ³£½à£¬£¬£¬£¬£¬ £¬£¬£¬µÈ
10.ÅàĪɳëÄÖÎÁÆÄÑÖÎÐÔÉöÐÔѪÐéµÄÓÐÓÃÐÔÓëÇå¾²ÐÔ
×÷ÕߣºÄϾ©Ò½¿Æ´óѧÁ¥ÊôÌ©ÖÝÈËÃñÒ½Ôº ²Üæºæ£¬£¬£¬£¬£¬ £¬£¬£¬µÈ
11.ÅàĪɳëÄÖÎÁÆά³ÖÐÔ¸¹Ä¤Í¸Îö»¼ÕßÉöÐÔѪÐéµÄÁÆЧÊÓ²ì
×÷ÕߣºÉòÑôÊеÚËÄÈËÃñÒ½Ôº ¹ù࣬£¬£¬£¬£¬ £¬£¬£¬µÈ
12.²¡Àý±¨¸æ£ºÅàĪɳëÄÍŽáÂÞɳ˾ËûÔÚ´¿ºìϸ°ûÔÙÉúÕÏ°ÐÔѪÐéÖÎÁÆÖеÄÓ¦ÓÃ
×÷Õߣº°²¶¨ÊеÚÒ»ÈËÃñÒ½Ôº ÀîÐø÷£¬£¬£¬£¬£¬ £¬£¬£¬µÈ
×Ô2023Äê6ÔÂÉÏÊÐÒÔÀ´£¬£¬£¬£¬£¬ £¬£¬£¬Ê¥ÂÞÀ³?ÒÑÆÕ±éÓÃÓÚCKDÏà¹ØѪÐéµÄÖÎÁÆ£¬£¬£¬£¬£¬ £¬£¬£¬²¢ÏȺó±»ÄÉÈ롶³¤Ð§ºìϸ°ûÌìÉú´Ì¼¤¼ÁÖÎÁÆÉöÐÔѪÐéÖйúר¼Ò¹²Ê¶£¨2024Äê°æ£©¡·[2]¡¢¡¶Ö¸µ¼ÉöÐÔѪÐ黼Õß×ÔÎÒÖÎÀíµÄÖйúר¼Ò¹²Ê¶(2024 °æ)¡·[3]ÒÔ¼°¡¶ÑÓ»ºÂýÐÔÉöÔಡϣÍûÁÙ´²ÖÎÀíÖ¸ÄÏ£¨2025Äê°æ£©¡·[4]¶à¸öÖ¸ÄϹ²Ê¶ÍƼö¡£¡£¡£¡£¡£¡£
±¾´Î´ó»áÈëÑ¡µÄÉÏÊöÑо¿Ð§¹û²»µ«¸»ºñÁËÊ¥ÂÞÀ³?µÄÑÖ¤Ö¤¾Ý£¬£¬£¬£¬£¬ £¬£¬£¬ÉÐÓÐÖúÓÚÍƶ¯ÉöÐÔѪÐéÁìÓòµÄÉú³¤£¬£¬£¬£¬£¬ £¬£¬£¬ÎªÔö½øº£ÄÚCKDѪÐéµÄ¹æ·¶»¯ÖÎÁÆ¡¢Ìá¸ßÉöÐÔѪÐ黼ÕßµÄÉúÑÄÔ¤ºóТ˳ʵÁ¦¡£¡£¡£¡£¡£¡£
²Î¿¼ÎÄÏ×£º
1.https://ccsn2025.sciconf.cn/cn/web/abstract-search/31448
2.ÖлªÉöÔಡÔÓÖ¾,2024,40(2):146-157.
3.ÖйúѪҺ¾»»¯,2025,24(1):1-12
4.ÖлªÉöÔಡÔÓÖ¾, 2025, 41(6): 455-488.
¹ØÓÚº²ÉÖÆÒ©
ÃâÔðÉùÃ÷
Ç°Õ°ÐÔ˵Ã÷
